GLP-1 Innovation and Oversight Shaping the Future of Therapeutic Access
September 16, 2025
Explore the clinical promise of GLP-1 therapies alongside the need for more regulatory oversight.
GLP-1 receptor agonists have become blockbuster therapies for obesity and diabetes and are now being explored for broader use across various health conditions. Yet the rapid growth of compounded versions, often produced without FDA oversight, presents serious safety and compliance risks.
This Summit brings together industry experts to examine both the expanding therapeutic potential and urgent need for stronger oversight. Attendees will gain insight into the regulatory, clinical, and commercial dynamics shaping the future of GLP-1 access and how the industry can respond accordingly.
Gain access to on demand fireside chats and keynote presentations from the world’s leading innovators, vendors and evangelists.
September 16, 2025
10:00AM EDT | 3:00PM BST
Buyer Beware: How Weak Oversight of Compounded GLP-1s Threatens Patient Safety
| Learn more
Something went wrong. Please try again.
2:00PM EDT | 7:00PM BST
Beyond Obesity and Diabetes: Exploring the Expanded Therapeutic Potential of GLP-1s
| Learn more
Something went wrong. Please try again.
Presenters
Jayne Hornung
Joseph P. Schacht, Ph.D.
Patrick F. Smith, PharmD
Nicole Snow, PharmD, BCSCP, CSP
Peter Pitts
Audience
MDs, Heads, EVPs, SVPs, VPs, Directors, Managers, Practitioners, and Consultants within:
Pharma / Life Sciences / Medicine
Digital CMC / Digital Technologies
Data & Analytics / Strategy
Business Operations
Healthcare Operations / Healthcare Innovation
Medical Value
Pharmacogenomics
Cell & Gene Therapy
Healthcare Pricing & Strategy
Previous Speaking and Attending Companies
AbbVie Inc., Academy of Managed Care Pharmacy, Aetna Inc, Alcon Laboratories, Inc., Aliados Health, Alkermes, Inc., Alnylam Pharmaceuticals, Inc., Astellas Pharma Inc., AstraZeneca Plc, Atrium Health, Avalere Health LLC, Ballad Health, Bangkok Hospital, Bausch Health, Baxter International, Bayer AG, Benefis Healthcare, Biossil, BJC HealthCare, Blue Cross and Blue Shield of North Carolina, Bluestream Health, Boston Medical Center, Bristol-Myers Squibb Company, CancerCare Manitoba Foundation Inc., Care2Care International, Catalia Health, Cepheid Inc., Centers for Disease Control and Prevention
Children’s Medical Center, Clinuvel Pharmaceuticals Ltd, Colorado Pharmacy Society, CommonSpirit Health, Duke University, EagleForce Health LLC, Essentia Health, Free Market Health, Genentech, Inc., Gold Coast Health Plan, Grifols Inc., Guidewell Hawler Medical University, Healthcentric Advisors, Highmark Health, Hoffmann-La Roche Inc., Hudson Valley Heart Center, Indiana University Health, Intermountain Health Care, InC., J.P. Morgan & Co., Kaiser Permanente, Lupin Pharmaceuticals, M&T Bank, Marathon Health, Mayo Foundation for Medical Education & Research
Medical Research Council, Medicare Payment Advisory Commission, Medstar, Merge Healthcare, Morgan Stanley & Co., Mount Sinai Hospital, MountainStar Healthcare Network, MVP Health Care Inc., National Institutes of Health, National Nurses In Business Association, Inc., naviHealth, New York University Langone Medical Center, Northwell Health, Ohio Pharmacists Association, Oklahoma Health Care Authority, Oklahoma State University, Pacira Pharmaceuticals, Palomar Health, Penn Medicine, Penn State Health, PerkinElmer, Pharmaceutical Care Management Association
PrimeWest Health, Renown Health Foundation Rhode Island Department of Health, Sabio Health, Sanford Health, Story Health, St Petersburg State University, Strathmore University, Superior Biologics, Tabia Health, Taiho Oncology, Inc., Takeda Pharmaceutical Company, Texas Tech University, The Advisory Board Company, The Merck Group, The Wellness Centre, UnitedHealthcare, University of Michigan, University of New Hampshire, University of North Carolina at Chapel Hill, University of Pittsburgh Medical Center, Walgreens, West Pharmaceutical Services Inc., WEX Health, and more!